Agenda
09.00 – 09.30
Opening statements
09.30 – 09.45
Introduction to the program
09.45 – 10.30
Evolution in the diagnostic of rare genetic epilepsies
When Before genetics: clinical diagnosis of rare epilepsies
The genetic revolution in rare epilepsies
10.30 – 11.00
Coffee break
11.00 – 12.30
Treating seizures: symptomatic treatment of Dravet syndrome
Treatment decisions in pharmacoresistant epilepsy patients
The development of Epidiolex
The development of Fintepla
The development of OV935
12.30 – 13.30
Lunch break
13.30 – 14.50
Treating genes: disease-modifying treatment of Dravet syndrome
Activation of Nav1.1
Rescuing haploinsufficiency with ASOs
Restoring gene expression with gene therapy
When might gene editing be ready for the show
14.50 – 15.10
Patient organizations as partners in drug development
15.10 – 16.00
Open discussions and closure